<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01106235</url>
  </required_header>
  <id_info>
    <org_study_id>2390.00</org_study_id>
    <secondary_id>NCI-2010-00146</secondary_id>
    <nct_id>NCT01106235</nct_id>
  </id_info>
  <brief_title>Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Metastatic Melanoma</brief_title>
  <official_title>Phase I Study To Evaluate Cellular Adoptive Immunotherapy Using Autologous IL-21 Modulated CD8+ Antigen-Specific T Cells For Patients With Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Aldesleukin may stimulate lymphocytes to kill melanoma cells. Treating lymphocytes&#xD;
      with interleukin-21 in the laboratory may help the lymphocytes kill more tumor cells when&#xD;
      they are put back in the body. Giving therapeutic autologous lymphocytes together with&#xD;
      cyclophosphamide and aldesleukin may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of giving therapeutic&#xD;
      autologous lymphocytes together with cyclophosphamide and aldesleukin in treating patients&#xD;
      with metastatic melanoma&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Assess the safety and toxicity of adoptively transferred interleukin (IL)-21 modulated&#xD;
      cytotoxic T-lymphocyte (CTL) targeting a melanoma associated antigen in patients following&#xD;
      cyclophosphamide conditioning.&#xD;
&#xD;
      II. Evaluate the functional and numeric in vivo persistence of adoptively transferred IL-21&#xD;
      modulated CTL and factors contributing to immunopotentiation in patients receiving IL-21&#xD;
      modulated CTL following cyclophosphamide conditioning.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Evaluate the antitumor effect of adoptively transferred IL-21 modulated CD8+&#xD;
      antigen-specific CTL following cyclophosphamide conditioning and post-infusion IL-2.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive cyclophosphamide intravenously (IV) on days -3 and -2 followed by an&#xD;
      infusion of IL-21 modulated, melanoma antigen recognized by T cell (MART)-1 specific CD8+&#xD;
      cytotoxic T lymphocytes over 30-60 minutes on day 0. Beginning within 24 hours of T-cell&#xD;
      infusion, patients receive low-dose aldesleukin subcutaneously (SC) twice daily (BID) for 14&#xD;
      days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed for 8-10 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>April 2010</start_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and toxicity as assessed by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v 3.0</measure>
    <time_frame>10 weeks post infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional and numeric in vivo persistence of adoptively transferred IL-21 modulated CTL and factors contributing to immunopotentiation in patients receiving IL-21 modulated CTL following cyclophosphamide conditioning</measure>
    <time_frame>10 weeks post infusion</time_frame>
    <description>Descriptive statistics (average, median standard deviation and student's t test) will be used to determine if an increase in the duration of in vivo persistence is observed using IL-21 modulated T cells when retrospectively compared with T cells generated under standard culture conditions (no IL-21 exposure in vitro).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>In vivo persistence and anti-tumor effect of the infused IL-21 modulated CTL</measure>
    <time_frame>10 weeks post infusion</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Stage IV Melanoma</condition>
  <arm_group>
    <arm_group_label>Treatment (immunostimulant, autologous lymphocytes, and chemo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive cyclophosphamide IV on days -3 and -2 followed by an infusion of IL-21 modulated, MART-1 specific CD8+ cytotoxic T lymphocytes over 30-60 minutes on day 0. Beginning within 24 hours of T cell infusion, patients receive low-dose aldesleukin SC BID for 14 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic autologous lymphocytes</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (immunostimulant, autologous lymphocytes, and chemo)</arm_group_label>
    <other_name>AL</other_name>
    <other_name>Autologous Lymphocytes</other_name>
    <other_name>autologous T cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Treatment (immunostimulant, autologous lymphocytes, and chemo)</arm_group_label>
    <other_name>IL-2</other_name>
    <other_name>Proleukin</other_name>
    <other_name>recombinant human interleukin-2</other_name>
    <other_name>recombinant interleukin-2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (immunostimulant, autologous lymphocytes, and chemo)</arm_group_label>
    <other_name>CPM</other_name>
    <other_name>CTX</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Endoxan</other_name>
    <other_name>Endoxana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsy</intervention_name>
    <description>Optional correlative studies</description>
    <arm_group_label>Treatment (immunostimulant, autologous lymphocytes, and chemo)</arm_group_label>
    <other_name>biopsies</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  FOR LEUKAPHERESIS:&#xD;
&#xD;
          -  Pulse &gt; 45 or &lt; 120&#xD;
&#xD;
          -  Weight &gt;= 45 kg&#xD;
&#xD;
          -  Temperature =&lt; 38 Celsius (C) (=&lt; 100.4 Fahrenheit [F])&#xD;
&#xD;
          -  White blood cells (WBC) &gt;= 3000&#xD;
&#xD;
          -  Hematocrit (HCT) &gt;= 30%&#xD;
&#xD;
          -  Platelets &gt;= 100,000&#xD;
&#xD;
          -  FOR T CELL INFUSION:&#xD;
&#xD;
          -  Histopathological documentation of melanoma concurrent with the diagnosis of&#xD;
             metastatic disease&#xD;
&#xD;
          -  Tumor expression of MART-1 (2+ staining or &gt; 25%) by immunohistochemistry (IHC)&#xD;
&#xD;
          -  Able to tolerate high-dose cyclophosphamide&#xD;
&#xD;
          -  Expression of human leukocyte antigen (HLA)-A2&#xD;
&#xD;
          -  Zubrod performance status of 0-1&#xD;
&#xD;
          -  Bi-dimensionally measurable disease by palpation on clinical exam, or radiographic&#xD;
             imaging (X-ray, computed tomography [CT] scan)&#xD;
&#xD;
          -  Normal cardiac stress test within 182 days prior to enrollment is required of all&#xD;
             patients over 50 years old or those with an abnormal electrocardiogram (ECG), any&#xD;
             history of cardiac disease, a family history of cardiac disease or hypertension&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant women, nursing mothers, men or women of reproductive ability who are&#xD;
             unwilling to use effective contraception or abstinence; women of childbearing&#xD;
             potential must have a negative pregnancy test within two weeks prior to entry&#xD;
&#xD;
          -  Serum creatinine &gt; 1.6 mg/dL or creatinine clearance (CrCl) &lt; 75 ml/min (calculated:&#xD;
             Cockcroft and Gault equation: CrCl = (140 - age) x ideal body weight (IBW)/(serum&#xD;
             creatinine [Scr] x 72) (x 0.85 for females)&#xD;
&#xD;
          -  Serum glutamic oxaloacetic transaminase (SGOT) &gt; 150 IU or &gt; 3 x upper limit of normal&#xD;
&#xD;
          -  Direct bilirubin &gt; 1.0 mg/dL&#xD;
&#xD;
          -  Prothrombin time &gt; 1.5 x control (in the absence of systemic anticoagulation)&#xD;
&#xD;
          -  Clinically significant pulmonary dysfunction, as determined by medical history and&#xD;
             physical exam; patients so identified will undergo pulmonary functions testing at the&#xD;
             discretion of their primary physician&#xD;
&#xD;
          -  Significant cardiovascular abnormalities as defined by any one of the following:&#xD;
&#xD;
          -  Congestive heart failure,&#xD;
&#xD;
          -  Clinically significant hypotension,&#xD;
&#xD;
          -  Symptoms of coronary artery disease,&#xD;
&#xD;
          -  Presence of cardiac arrhythmias on electrocardiogram (EKG) requiring drug therapy&#xD;
&#xD;
          -  Symptomatic central nervous system metastases greater than 1 cm at time of therapy;&#xD;
             patients with 1-2 asymptomatic, less than 1cm brain/central nervous system (CNS)&#xD;
             metastases without significant edema may be considered for treatment; if&#xD;
             sub-centimeter CNS lesions are noted at study entry, then a repeat imaging will be&#xD;
             performed if more than 3 weeks have elapsed from the last scan; patients will not be&#xD;
             treated if CNS lesions are &gt; 1 cm or if patient is symptomatic from brain metastasis&#xD;
&#xD;
          -  Patients with active infections or oral temperature &gt; 38.2 C within 72 hours of study&#xD;
             entry or systemic infection requiring chronic maintenance or suppressive therapy&#xD;
&#xD;
          -  Chemotherapeutic agents (standard or experimental), radiation therapy, or other&#xD;
             immunosuppressive therapies less than 3 weeks prior to T cell therapy; (patients with&#xD;
             bulky disease may undergo cytoreductive chemotherapy but treatment will be&#xD;
             discontinued at least 3 weeks prior to T cell therapy)&#xD;
&#xD;
          -  Clinically significant autoimmune disorders or conditions of immunosuppression;&#xD;
             patients with acquired immunodeficiency syndrome (AIDS) or human immunodeficiency&#xD;
             virus (HIV)-1 associated complex or known to HIV antibody seropositive or known to be&#xD;
             recently polymerase chain reaction positive (PCR+) for hepatitis are not eligible for&#xD;
             this study; virology testing will be done within 6 months of T cell infusion; the&#xD;
             severely depressed immune system found in these infected patients and the possibility&#xD;
             of premature death would compromise study objectives&#xD;
&#xD;
          -  Patients who, in the opinion of their physician, are not clinically suited for&#xD;
             high-dose cytoxan&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cassian Yee</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <study_first_submitted>April 8, 2010</study_first_submitted>
  <study_first_submitted_qc>April 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2010</study_first_posted>
  <last_update_submitted>December 20, 2011</last_update_submitted>
  <last_update_submitted_qc>December 20, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 21, 2011</last_update_posted>
  <responsible_party>
    <name_title>Yee, Cassian</name_title>
    <organization>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

